Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma

Systemic therapy for metastatic renal cell carcinoma has continuously evolved over the last two decades. Significant improvements in overall survival and quality of life of patients with advanced disease have been observed. With the approval of combination therapies with PD(L)-1 immune checkpoint in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marc-Oliver Grimm, Katharina Leucht, Susan Foller
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	renal cell carcinoma immune-checkpoint inhibitors axitinib avelumab nivolumab ipilimumab Medicine R
Acceso en línea:	https://doaj.org/article/b7721a5e28b94164a3b0a80090376961
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b7721a5e28b94164a3b0a80090376961
record_format	dspace
spelling	oai:doaj.org-article:b7721a5e28b94164a3b0a800903769612021-11-25T18:01:53ZRisk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma10.3390/jcm102253392077-0383https://doaj.org/article/b7721a5e28b94164a3b0a800903769612021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5339https://doaj.org/toc/2077-0383Systemic therapy for metastatic renal cell carcinoma has continuously evolved over the last two decades. Significant improvements in overall survival and quality of life of patients with advanced disease have been observed. With the approval of combination therapies with PD(L)-1 immune checkpoint inhibitors (ICI) as first-line therapy in 2019, the previous standard VEGFR-TKI monotherapy has been replaced as the primary treatment option. In addition to immunotherapy with nivolumab and ipilimumab, three VEGFR-TKI/ICI combinations are now approved. Therapy selection should be preceded by risk stratification using defined criteria from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical parameters, as well as detailed patient counseling on differences in the efficacy profile (response rate, long-term progression-free survival), potential side effects, and impact on quality of life, are of key importance in the individual treatment decision.Marc-Oliver GrimmKatharina LeuchtSusan FollerMDPI AGarticlerenal cell carcinomaimmune-checkpoint inhibitorsaxitinibavelumabnivolumabipilimumabMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5339, p 5339 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	renal cell carcinoma immune-checkpoint inhibitors axitinib avelumab nivolumab ipilimumab Medicine R
spellingShingle	renal cell carcinoma immune-checkpoint inhibitors axitinib avelumab nivolumab ipilimumab Medicine R Marc-Oliver Grimm Katharina Leucht Susan Foller Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
description	Systemic therapy for metastatic renal cell carcinoma has continuously evolved over the last two decades. Significant improvements in overall survival and quality of life of patients with advanced disease have been observed. With the approval of combination therapies with PD(L)-1 immune checkpoint inhibitors (ICI) as first-line therapy in 2019, the previous standard VEGFR-TKI monotherapy has been replaced as the primary treatment option. In addition to immunotherapy with nivolumab and ipilimumab, three VEGFR-TKI/ICI combinations are now approved. Therapy selection should be preceded by risk stratification using defined criteria from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical parameters, as well as detailed patient counseling on differences in the efficacy profile (response rate, long-term progression-free survival), potential side effects, and impact on quality of life, are of key importance in the individual treatment decision.
format	article
author	Marc-Oliver Grimm Katharina Leucht Susan Foller
author_facet	Marc-Oliver Grimm Katharina Leucht Susan Foller
author_sort	Marc-Oliver Grimm
title	Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
title_short	Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
title_full	Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
title_fullStr	Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
title_full_unstemmed	Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
title_sort	risk stratification and treatment algorithm of metastatic renal cell carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b7721a5e28b94164a3b0a80090376961
work_keys_str_mv	AT marcolivergrimm riskstratificationandtreatmentalgorithmofmetastaticrenalcellcarcinoma AT katharinaleucht riskstratificationandtreatmentalgorithmofmetastaticrenalcellcarcinoma AT susanfoller riskstratificationandtreatmentalgorithmofmetastaticrenalcellcarcinoma
_version_	1718411703595565056

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma

Ejemplares similares